BARIATRIC SURGERY CLINICAL RESEARCH CONSORTIUM

肥胖症研究的一个主要目标是确定肥胖症的病理生理学，作为预防肥胖症的基础。 和/或有效地治疗疾病。涉及减肥手术患者的研究领域可能 包括：1）确定最佳手术方法，2）识别生物学和遗传学差异， 影响合并症的发展和手术结果，以及3）利用该人群作为模型 用于研究肥胖症的发病机制和对治疗的反应。我们建议肥胖研究 临床研究联盟（BSCRC）采用了一个全面的关系数据库，其中包括 所有临床中心（CC）均可使用的参数，如基本人体测量学、身体测量 组成、临床和手术史以及定量合并症量表的记录。这种规模 对17种与肥胖相关的合并症进行评分，包括糖尿病、高血压和高脂血症，以及 利用治疗作为衡量症状严重程度的标准。进一步完善科摩罗比额表 BSCRC参与者可能需要评分。该量表将使合并症与 mRNA表达谱和内分泌反应。 加州大学戴维斯分校提出了两个具体的协议，由BSCRC进行。短期方案将测量， 采用定量PCR方法，检测肥胖相关基因在皮下和皮下组织的mRNA表达水平， 网膜脂肪，肝脏和肠道的减肥手术患者在手术时间。身体测量 包括身体脂肪的分布，对胃旁路的内分泌反应，以及临床 合并症评分将允许从手术时间到时间点2的受试者的详细表型 这将是了解并发症的变化的重要的第一步。 相似肥胖受试者之间的发生率。长期方案为3-5年纵向研究 研究胃转流术的反应与激素活性、身体组成和身体状况的关系 活动在这个阶段，与术前遗传和内分泌标志物的相关性在短时间内得到证实。 长期研究以及合并症史评分将确定哪些患者最受益 胃旁路手术BSCRC积累的这些数据和其他数据将为建立 进一步研究肥胖合并症及其对手术治疗的反应。

A primary objective of obesity research is to define the pathophysiology of obesity as a basis for preventing and/or effectively treating the disease. The areas for research involving bariatric surgery patients may include: 1) defining optimal surgical approaches, 2) identification of biological and genetic differences that influence development of comorbidities and outcomes of surgery, and 3) utilizing this population as a model for study of the pathogenesis and response to treatment of obesity. We propose that the Bariatric Research Clinical Research Consortium (BSCRC) employ a comprehensive relational database that includes parameters readily available to all Clinical Centers (CCs), such as basic anthropometrics, measures of body composition, clinical and surgical history, and recording of a quantitative comorbidity scale. This scale scores each of 17 comorbidities related to obesity, including diabetes, hypertension, and hyperlipidemia, and utilizes treatment as a gauge for the severity of symptoms. Further refinement to the comorbidity scale grading may be required by BSCRC participants. This scale will enable comorbidities to be correlated with mRNA expression profiles and endocrine response. UC Davis proposes two specific protocols for conduct by the BSCRC. The short term protocol will measure, using quantitative PCR, the mRNA expression level of obesity related genes in the subcutaneous and omental fat, liver, and intestine of bariatric surgery patients at the time of operation. Measures of body composition including the distribution of body fat, endocrine response to gastric bypass, and the clinical comorbidity scores will allow detailed phenotyping of the subjects from the time of operation to timepoints 2 years post-op. This will be an important initial step towards understanding the variation of comorbidity occurrence between subjects of similar adiposity. The longer term protocol will be a 3-5 year longitudinal study of the response to gastric bypass in relation to hormone activity, body composition, and physical activity. At this phase, correlation with the preoperative genetic and endocrine markers derived in the short term study, as well as history of comorbidity scores, would identify those patients who would most benefit from gastric bypass. This and other data accumulated by the BSCRC will provide a basis for establishment of further studies of obesity comorbidities and their response to surgical treatment.